Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
NASDAQ:ITRM
Price:
1.67 USD
6.37%
Market Closed
Updated:
Apr 27, 2024
Iterum Therapeutics PLC
Cash from Operating Activities
|
Iterum Therapeutics PLC
Cash from Operating Activities Peer Comparison
Comparables:
PRGO
JAZZ
AVDL
G
GHRS
COPN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Cash from Operating Activities
-$39.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Cash from Operating Activities
$405.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Cash from Operating Activities
$1.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Cash from Operating Activities
-$128.5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-20%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Cash from Operating Activities
-$33.3m
|
CAGR 3-Years
-366%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Cash from Operating Activities
€33.6m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
See Also
What is Iterum Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-39.3m
USD
-39.3m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Cash from Operating Activities amounts to -39.3m USD.
What is Iterum Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
13%
13%
Over the last year, the Cash from Operating Activities growth was -113%. The average annual Cash from Operating Activities growth rates for Iterum Therapeutics PLC have been 10% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
